aTYR PHARMA (ATYR) Return on Sales (2019 - 2025)
Historic Return on Sales for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to 140.76%.
- aTYR PHARMA's Return on Sales rose 1488200.0% to 140.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 413.95%, marking a year-over-year decrease of 1243700.0%. This contributed to the annual value of 289.0% for FY2024, which is 1334200.0% down from last year.
- Latest data reveals that aTYR PHARMA reported Return on Sales of 140.76% as of Q3 2025, which was up 1488200.0% from 289.0% recorded in Q4 2024.
- Over the past 5 years, aTYR PHARMA's Return on Sales peaked at 0.77% during Q4 2022, and registered a low of 289.59% during Q3 2024.
- Over the past 5 years, aTYR PHARMA's median Return on Sales value was 35.74% (recorded in 2023), while the average stood at 85.5%.
- In the last 5 years, aTYR PHARMA's Return on Sales crashed by -2538500bps in 2024 and then surged by 1488200bps in 2025.
- aTYR PHARMA's Return on Sales (Quarter) stood at 2.41% in 2021, then surged by 68bps to 0.77% in 2022, then plummeted by -20225bps to 155.58% in 2023, then plummeted by -86bps to 289.0% in 2024, then skyrocketed by 51bps to 140.76% in 2025.
- Its last three reported values are 140.76% in Q3 2025, 289.0% for Q4 2024, and 289.59% during Q3 2024.